Skip to main content
  • Register
  • Help
  • Contact us

Leap Therapeutics Inc (LPTX) USD0.001

Sell:$1.60 Buy:$1.73 Change: $0.02 (1.25%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
Change: $0.02 (1.25%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
Change: $0.02 (1.25%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Leap Therapeutics, Inc. is a biopharmaceutical company developing therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. The Company’s programs are monoclonal antibodies that target key cellular pathways that enable cancer to grow and spread and specific mechanisms that activate the body’s immune system to identify and attack cancer. DKN-01 and TRX518 are its clinical stage programs. DKN-01 is a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. TRX518 is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor (GITR). GITR is a receptor found on the surface of a wide range of immune cells.

Contact details

47 Thorndike St Ste B1-1
United States
+1 (617) 2524343

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$98.46 million
Shares in issue:
59.67 million
United States
US dollar

Key personnel

  • Christopher Mirabelli
    Chairman of the Board
  • Douglas Onsi
    President, Chief Executive Officer, Director
  • Augustine Lawlor
    Chief Operating Officer
  • Mark O'Mahony
    Chief Manufacturing Officer
  • Cynthia Sirard
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.